Posts by John

Discover the hidden operational and patient-care challenges at investigative sites when corporate acquisitions trigger the sudden closure of Phase 3 trials.

Explore how the synergy between englumafusp and glofitamab is transforming oncology trial design and setting new benchmarks for bispecific cancer therapy.

Akeso has launched a Phase II trial for AK146D1, a new treatment for advanced NSCLC. Learn about this critical development in lung cancer clinical research.

Novartis faces investor scrutiny as its drug pipeline faces a critical valuation test. Discover what the future holds for its clinical strategy.

Natco Pharma shares rise following US FDA tentative approval for a new generic cancer medication, signaling a major boost for its oncology portfolio.

Telangana and Microsoft join forces to boost green skills, empowering the local workforce with AI-driven training to lead the global shift toward sustainability.

A novel mRNA-based vaccine has shown potential in an early-stage trial for pancreatic cancer. Discover how this personalized therapy targets tumor cells.

Explore the latest data on XmAb819 for advanced renal cell carcinoma. Discover how this novel bispecific antibody is performing in Phase 1 clinical trials.

New research highlights the hidden fragility of pragmatic clinical trials. Discover why real-world evidence requires better rigor and data integrity.

The psychedelic medicine market is surging as investment and clinical data point toward a new era in treating depression and PTSD. Read the latest trends.